Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SOPE OMOWALE OLUGBILE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1427344175
CMS profile
1390730
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,165.60

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,088.52 87
Education $77.08 5

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SOPE OMOWALE OLUGBILE

NPI 1427344175 · CMS profile ID 1390730

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427344175?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SOPE OMOWALE OLUGBILE, NPI 1427344175, CMS profile ID 1390730. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427344175?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SOPE OMOWALE OLUGBILE, NPI 1427344175, CMS profile ID 1390730. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427344175?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SOPE OMOWALE OLUGBILE, NPI 1427344175, CMS profile ID 1390730, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427344175?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $2,165.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $23.9506/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234484862 CMS
Alexion Pharmaceuticals, Inc. $20.3306/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202975646 CMS
Eisai Inc. $23.5106/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244513399 CMS
Merck Sharp & Dohme LLC $27.3806/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238322896 CMS
AstraZeneca Pharmaceuticals LP $29.7206/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206736829 CMS
Adaptive Biotechnologies Corporation $22.0006/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254936533 CMS
GENZYME CORPORATION $20.9906/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233469745 CMS
Daiichi Sankyo Inc. $21.0206/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197078959 CMS
Tempus AI, Inc $28.7606/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250349693 CMS
Merck Sharp & Dohme LLC $22.0205/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238360823 CMS
PFIZER INC. $24.1005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229214454 CMS
BeOne Medicines USA, Inc. $25.3805/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202892980 CMS
Coherus Oncology, Inc. $24.1905/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235239723 CMS
Janssen Biotech, Inc. $22.8005/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175342283 CMS
Agios Pharmaceuticals, Inc. $20.3705/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253250213 CMS
AstraZeneca Pharmaceuticals LP $26.3205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206668272 CMS
Merck Sharp & Dohme LLC $21.1804/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238097152 CMS
Fennec Pharmaceuticals, Inc. $24.9204/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250855271 CMS
EMD Serono, Inc. $24.0804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236890098 CMS
Eisai Inc. $19.9604/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244513397 CMS
Daiichi Sankyo Inc. $19.2104/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197097867 CMS
Novartis Pharmaceuticals Corporation $21.5204/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200769942 CMS
Bayer Healthcare Pharmaceuticals Inc. $25.4904/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225677987 CMS
GlaxoSmithKline, LLC. $17.6604/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190999158 CMS
Genentech USA, Inc. $18.0503/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211591443 CMS
Daiichi Sankyo Inc. $23.1903/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197058839 CMS
AstraZeneca Pharmaceuticals LP $28.4603/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206999154 CMS
Eisai Inc. $22.6203/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244513395 CMS
ARRAY BIOPHARMA INC $16.1503/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229068208 CMS
ARRAY BIOPHARMA INC $1.0803/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229562012 CMS
ARRAY BIOPHARMA INC $0.7103/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229568839 CMS
PFIZER INC. $13.0403/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1229568073 CMS
PFIZER INC. $16.0103/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1230820583 CMS
Alexion Pharmaceuticals, Inc. $23.3603/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202940912 CMS
Astellas Pharma US Inc $27.0303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238749854 CMS
Eisai Inc. $17.6503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244513393 CMS
Exelixis Inc. $25.0803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218804741 CMS
AstraZeneca Pharmaceuticals LP $30.9103/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206580639 CMS
Astellas Pharma US Inc $28.4602/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238602722 CMS
Karyopharm Therapeutics Inc. $23.9601/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246652307 CMS
Janssen Biotech, Inc. $17.4201/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175341805 CMS
PFIZER INC. $18.2301/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228999779 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $22.71 2
PY2024 $184.48 5
PY2025 $2,165.60 92

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $74,333.80 8
PY2019 Principal investigator $119,976.05 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

8 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,180.60 11/13/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175390228
Principal investigator 1 Janssen Research & Development, LLC $5,092.00 09/12/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390200
Principal investigator 1 Janssen Research & Development, LLC $3,015.00 09/01/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390283
Principal investigator 1 Janssen Research & Development, LLC $13,020.00 07/22/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390217
Principal investigator 1 Janssen Research & Development, LLC $800.00 07/07/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390188
Principal investigator 1 Janssen Research & Development, LLC $12,202.00 07/01/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390183
Principal investigator 1 Janssen Research & Development, LLC $5,036.20 05/20/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390176
Principal investigator 1 Janssen Research & Development, LLC $32,988.00 03/10/2025 Non-covered Recipient Entity
PIEDMONT HEALTHCARE INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175390167